Oncolix Inc (ONCX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Oncolix Inc (ONCX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8046
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oncolix Inc (Oncolix) is a clinical stage biotechnology company. It is developing a targeted therapeutic protein, Prolanta for the treatment of ovarian, breast and other cancers. Prolanta is a recombinant analogue to the human prolactin and acts as an antagonist to the prolactin receptor. Oncolix partners with other organizations such as BioVectra, Inc and Greenville Hospital System for the further development of Prolanta. It is also a member of BIO and BioHouston. The company works with various collaborators at The University Texas MD Anderson Cancer Center and developed the efficiency data in ovarian cancer. Oncolix is headquartered in Houston, Texas, the US.

Oncolix Inc (ONCX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncolix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Oncolix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oncolix Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Oncolix Raises USD0.3 Million in Venture Financing 10
Oncolix Raises USD0.2 Million in Financing 11
Oncolix Raises USD0.15 Million in Venture Financing 12
Oncolix Raises USD4.2 Million in Series A Financing 13
Oncolix Plans To Raise Additional US$5 Million In Venture Financing 14
Oncolix Raises US$2.4 Million In Venture Financing 15
Equity Offering 16
Oncolix Files Registration Statement for Public Offering of Shares 16
Debt Offering 17
Oncolix Raises USD1.2 Million in Public Offering of 10% Notes Due 2019 17
Acquisition 18
Advanced Environmental Petroleum Producers Acquires Oncolix in Reverse Acquisition 18
Oncolix Inc – Key Competitors 19
Oncolix Inc – Key Employees 20
Oncolix Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Jul 24, 2018: Centene reports 2018 second quarter results and updates 2018 guidance 22
Corporate Communications 24
Jun 26, 2018: Oncolix names Wall Street Veteran, Sherry Grisewood, to Its board of directors 24
Dec 18, 2017: Oncolix Announces Approval for Listing on OTC-QB 25
Dec 05, 2017: Oncolix Announces Submission of Application for Listing on OTC-QB 26
Product News 27
12/04/2017: Oncolix Expands Board of Directors with New Appointment 27
Clinical Trials 28
Jan 31, 2018: Oncolix Sponsors Additional Research with MD Anderson Cancer Center 28
Jan 08, 2018: Oncolix Initiates Patient Recruitment of Second Cohort of Prolanta Phase 1 Trial in Advanced Ovarian Cancer 29
Nov 28, 2017: Oncolix Continues Progress as an Emerging Clinical-Stage Biopharmaceutical Company with Stock Ticker Symbol Change to ONCX 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Oncolix Inc, Pharmaceuticals & Healthcare, Key Facts 2
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncolix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncolix Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Oncolix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Oncolix Raises USD0.3 Million in Venture Financing 10
Oncolix Raises USD0.2 Million in Financing 11
Oncolix Raises USD0.15 Million in Venture Financing 12
Oncolix Raises USD4.2 Million in Series A Financing 13
Oncolix Plans To Raise Additional US$5 Million In Venture Financing 14
Oncolix Raises US$2.4 Million In Venture Financing 15
Oncolix Files Registration Statement for Public Offering of Shares 16
Oncolix Raises USD1.2 Million in Public Offering of 10% Notes Due 2019 17
Advanced Environmental Petroleum Producers Acquires Oncolix in Reverse Acquisition 18
Oncolix Inc, Key Competitors 19
Oncolix Inc, Key Employees 20

List of Figures
Oncolix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Oncolix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Oncolix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Oncolix Inc (ONCX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pharmascience Inc:企業のM&A・事業提携・投資動向
    Pharmascience Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pharmascience Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Nuance Communications, Inc.:企業の戦略・SWOT・財務情報
    Nuance Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nuance Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Takuma Co Ltd (6013):企業の財務・戦略的SWOT分析
    Takuma Co Ltd (6013) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Golden Queen Mining Co. Ltd.:企業の戦略・SWOT・財務情報
    Golden Queen Mining Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Golden Queen Mining Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Walmart Inc:企業のM&A・事業提携・投資動向
    Walmart Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Walmart Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Sherman & Howard LLC:企業の戦略的SWOT分析
    Sherman & Howard LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Kyochon F&B Co., Ltd.:企業の戦略・SWOT・財務分析
    Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kyochon F&B Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Viking Therapeutics Inc (VKTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Viking Therapeutics Inc (Viking Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. The company’s lead clinical program product candidate include VK5211, an orally available, non-steroidal se …
  • Smiths Group plc:企業の戦略・SWOT・財務分析
    Smiths Group plc - Strategy, SWOT and Corporate Finance Report Summary Smiths Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Intuit Inc (INTU):企業の財務・戦略的SWOT分析
    Intuit Inc (INTU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Advantest Corporation (6857):企業の財務・戦略的SWOT分析
    Advantest Corporation (6857) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Jiangxi Copper Company Limited:戦略・SWOT・企業財務分析
    Jiangxi Copper Company Limited - Strategy, SWOT and Corporate Finance Report Summary Jiangxi Copper Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Neuro Kinetics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Neuro Kinetics Inc (Neuro Kinetics) is a medical device manufacturing company that offers eye tracking technology and non-invasive neuro-otologic diagnostic testing solutions. The company’s products include VNG diagnostic systems, vestibular and neuro-otologic testing systems, software packa …
  • Iproteos SL:製薬・医療:M&Aディール及び事業提携情報
    Summary Iproteos SL (Iproteos) is a biotechnology company that develops therapeutic drugs for human diseases. The company develops drugs to treat various therapeutic indications such as cognitive impairment associated with schizophrenia, epilepsy, paediatric cancer, and others. It provides research …
  • NxStage Medical Inc (NXTM):企業の財務・戦略的SWOT分析
    NxStage Medical Inc (NXTM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Strabag SE:企業のM&A・事業提携・投資動向
    Strabag SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Strabag SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • AcelRx Pharmaceuticals Inc (ACRX):製薬・医療:M&Aディール及び事業提携情報
    Summary AcelRx Pharmaceuticals Inc (AcelRx), is a specialty pharmaceutical company that develops and commercializes drugs for the treatment of pain. The company’s lead product candidate, Dsuvia (known as Dzuveo outside the US), is a single sufentanil sublingual tablet for the treatment of moderate-t …
  • UNIQA Romania:企業の戦略・SWOT・財務情報
    UNIQA Romania - Strategy, SWOT and Corporate Finance Report Summary UNIQA Romania - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Beiersdorf AG:企業の戦略・SWOT・財務情報
    Beiersdorf AG - Strategy, SWOT and Corporate Finance Report Summary Beiersdorf AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Cavion LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Cavion LLC (Cavion), formerly Tau Therapeutics LLC is a clinical stage pharmaceutical company that develops modulators and drugs. The company researches and develops T-type calcium channel (Cav3) inhibitors for the treatment of neurologic and oncologic diseases. It provides pipeline products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆